FusionPharm, Inc.
FSPM
Other OTC0.00
USD
- -
- -
ISIN
US36113H1005
CUSIP
36113H100
Return %
Stock
S&P500
1Y
0.00
26.53
3Y
-50.00
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- William J. Sears
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 5850 East 58th Avenue Commerce City CO United States of America 80022
- IPO Date
- May 12, 1993
- Website
- fusionpharminc.com
- Similar Companies
- Business
- FusionPharm, Inc. (Ticker: FSPM) operates as a biotechnology company focused on developing innovative pharmaceutical products and medical solutions for the healthcare sector. The company offers a range of core products and services, including proprietary cannabinoid-based therapeutics, nutraceutical formulations, and medical cannabis delivery systems; advanced extraction technologies for pharmaceutical-grade compounds; and contract manufacturing services for branded and generic medications targeting pain management, inflammation, and neurological disorders. Founded in 2014 and headquartered in Denver, Colorado, FusionPharm serves target markets in North America, with expanding operations in Europe and Asia through distribution partnerships and regulatory-compliant facilities. In the last 1-2 years, FusionPharm has pursued significant strategic expansions, including a major funding round in 2024 that raised $25 million for scaling production capacity; the acquisition of a European subsidiary to enhance GMP-certified manufacturing; and the launch of a new line of sublingual cannabinoid sprays under the FusionRx brand. The company also formed a strategic alliance with a leading U.S. distributor for nationwide rollout of its flagship anti-inflammatory products and completed a reorganization to streamline its biotech and nutraceutical segments for improved operational efficiency. These developments position FusionPharm to capitalize on growing demand in the medical cannabis and precision medicine industries.